Carolyn Bolden-Watson
Research Subjects
Research Interests
Carolyn Bolden-Watson has a total of 100 co-authors. Here are the top co-authors by number of shared publications:
Alan Metz
GlaxoSmithKline (TLH, SRB, JAA, CB-W, RMJD, AM), Research Triangle Park, North Carolina, USA
6 shared publicationsElliott Richelson
Departments of Psychiatry and Psychology, and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224 USA
4 shared publicationsMichael A. Watson
Departments of Psychiatry and Psychology, and Pharmacology, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224 USA
3 shared publicationsBernadette Cusack
2 shared publicationsBrenda D. Jamerson
2 shared publicationsJing Zhou
2 shared publications
Latest Publications
- Open Access
- 6 May 2015
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 1 (1) , 23-36
Two randomized controlled trials of SB742457 in mild‐to‐moderate Alzheimer's disease
Background: Two previous studies of SB742457, a 5‐hydroxytryptamine (5‐HT 6 ) receptor antagonist, suggested the efficacy of improvements in cognition and global outcome in Alzheimer's disease (AD). Methods: Two randomized, placebo‐controlled trials investigated SB742457 15 and 35 mg daily in subjects with mild‐to‐moderate AD (Mini‐Mental Health State Examination [MMSE] 10–26). Study 1 (n = 576) investigated SB742457 and donepezil (5–10 mg daily) as monotherapy for 6 months. Study 2 (n = 684) investigated SB742457 in subjects who were maintained on donepezil. Coprimary endpoints at 24 weeks assessed cognition (AD Assessment Scale‐Cognitive Subscale [ADAS‐Cog]) and global outcome (Study 1: Clinician Interview‐Based Impression of Change Plus Caregiver Input [CIBIC+]; Study 2: Clinical Dementia Rating‐Sum of Boxes [CDR‐SB]). Safety was assessed throughout. Results: Both studies failed to achieve formal statistical significance for their primary objectives. Study 1: SB742457 monotherapy was not statistically significantly different from placebo on any endpoint. Donepezil improved CIBIC+ but not ADAS‐Cog. Study 2: SB742457 35 mg showed statistically significant differences relative to placebo for ADAS‐cog (weeks 12, 24, and 48, but not week 36), ADCS‐ADL (weeks 12–36, but not week 48), and CDR‐SB (week 12 only). Conclusion: Neither study met the overall criteria for success, but as an adjunct to donepezil, SB742457 was associated with sustained improvements for up to 48 weeks in cognition and ADL, compared with donepezil alone. Clinical Trial Registration: Clinicaltrials.gov : Study 1 NCT00708552 ; Study 2 NCT00710684 .
- 6 May 2015
- Published by Wiley in Alzheimer's & Dementia: Translational Research & Clinical Interventions
- Vol. 1 (1) , 23-36
Open AccessTwo randomized controlled trials of SB742457 in mild‐to‐moderate Alzheimer's disease
Background: Two previous studies of SB742457, a 5‐hydroxytryptamine (5‐HT 6 ) receptor antagonist, suggested the efficacy of improvements in cognition and global outcome in Alzheimer's disease (AD). Methods: Two randomized, placebo‐controlled trials investigated SB742457 15 and 35 mg daily in subjects with mild‐to‐moderate AD (Mini‐Mental Health State Examination [MMSE] 10–26). Study 1 (n = 576) investigated SB742457 and donepezil (5–10 mg daily) as monotherapy for 6 months. Study 2 (n = 684) investigated SB742457 in subjects who were maintained on donepezil. Coprimary endpoints at 24 weeks assessed cognition (AD Assessment Scale‐Cognitive Subscale [ADAS‐Cog]) and global outcome (Study 1: Clinician Interview‐Based Impression of Change Plus Caregiver Input [CIBIC+]; Study 2: Clinical Dementia Rating‐Sum of Boxes [CDR‐SB]). Safety was assessed throughout. Results: Both studies failed to achieve formal statistical significance for their primary objectives. Study 1: SB742457 monotherapy was not statistically significantly different from placebo on any endpoint. Donepezil improved CIBIC+ but not ADAS‐Cog. Study 2: SB742457 35 mg showed statistically significant differences relative to placebo for ADAS‐cog (weeks 12, 24, and 48, but not week 36), ADCS‐ADL (weeks 12–36, but not week 48), and CDR‐SB (week 12 only). Conclusion: Neither study met the overall criteria for success, but as an adjunct to donepezil, SB742457 was associated with sustained improvements for up to 48 weeks in cognition and ADL, compared with donepezil alone. Clinical Trial Registration: Clinicaltrials.gov : Study 1 NCT00708552 ; Study 2 NCT00710684 .
- 1 June 2008
- Published by SAGE Publications in Journal of Women's Health
- Vol. 17 (5) , 859-868
Restless Legs Syndrome in Women: A Review
Restless legs syndrome (RLS) is a neurological disorder with significant negative impact on sleep and quality of life, yet data suggest that it is frequently underdiagnosed. The clinical features, diagnosis, epidemiology, pathophysiology, and treatment options for RLS are reviewed and discussed, with particular emphasis on RLS in women. RLS is characterized by unpleasant sensations causing an urge to move the legs. RLS symptoms are exacerbated by rest, relieved by movement, and worse at night than during the day. The motor and sensory symptoms of RLS can have a negative impact on patients' sleep, resulting in a reduction in daytime functioning and overall quality of life. The prevalence of RLS is reported to increase with age and to be up to almost twice as high in women as in men. The explanation for this is unknown, although there is evidence that parity may be a factor. Diagnosis of RLS is made using four essential criteria based on the patient's report of sensorimotor symptoms. Several large, double-blind, placebo-controlled studies have demonstrated that dopamine agonists, such as ropinirole and pramipexole, are an efficacious first-line therapy for the treatment of RLS symptoms. As RLS is more prevalent in women, professionals working in the field of women's health need to be aware of this condition, its differential diagnosis, and the treatment options available. Accurate diagnosis is essential to facilitate appropriate management and treatment. Dopamine agonists have been shown to be an effective therapy for patients with moderate to severe symptoms of RLS.
- 1 June 2008
- Published by SAGE Publications in Journal of Women's Health
- Vol. 17 (5) , 859-868
Restless Legs Syndrome in Women: A Review
Restless legs syndrome (RLS) is a neurological disorder with significant negative impact on sleep and quality of life, yet data suggest that it is frequently underdiagnosed. The clinical features, diagnosis, epidemiology, pathophysiology, and treatment options for RLS are reviewed and discussed, with particular emphasis on RLS in women. RLS is characterized by unpleasant sensations causing an urge to move the legs. RLS symptoms are exacerbated by rest, relieved by movement, and worse at night than during the day. The motor and sensory symptoms of RLS can have a negative impact on patients' sleep, resulting in a reduction in daytime functioning and overall quality of life. The prevalence of RLS is reported to increase with age and to be up to almost twice as high in women as in men. The explanation for this is unknown, although there is evidence that parity may be a factor. Diagnosis of RLS is made using four essential criteria based on the patient's report of sensorimotor symptoms. Several large, double-blind, placebo-controlled studies have demonstrated that dopamine agonists, such as ropinirole and pramipexole, are an efficacious first-line therapy for the treatment of RLS symptoms. As RLS is more prevalent in women, professionals working in the field of women's health need to be aware of this condition, its differential diagnosis, and the treatment options available. Accurate diagnosis is essential to facilitate appropriate management and treatment. Dopamine agonists have been shown to be an effective therapy for patients with moderate to severe symptoms of RLS.
- 1 May 2002
- Published by Elsevier in Biological Psychiatry
- Vol. 51 (9) , 753-761
Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression
- 1 May 2002
- Published by Elsevier in Biological Psychiatry
- Vol. 51 (9) , 753-761
Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression
- Top Cited Papers
- 15 April 2002
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 63 (4) , 357-366
Prevalence of Sexual Dysfunction Among Newer Antidepressants
Sexual dysfunction commonly occurs during antidepressant treatment. However, the reported rates of sexual dysfunction vary across antidepressants and are typically underreported in product literature. The objectives of this study were (1) to estimate the prevalence of sexual dysfunction among patients taking newer antidepressants (bupropion immediate release [IR], bupropion sustained release [SR], citalopram, fluoxetine, mirtazapine, nefazodone, paroxetine, sertraline, venlafaxine, and venlafaxine extended release [XR]) and (2) to compare physician-perceived with patient-reported prevalence rates of antidepressant-associated sexual dysfunction. This cross-sectional, observational study was conducted in 1101 U.S. primary care clinics. Adult outpatients (4534 women and 1763 men) receiving antidepressant monotherapy were enrolled. The prevalence of sexual dysfunction was measured using the Changes in Sexual Functioning Questionnaire. In the overall population, bupropion IR (22%) and SR (25%) and nefazodone (28%) were associated with the lowest risk for sexual dysfunction, whereas selective serotonin reuptake inhibitor (SSRI) antidepressants, mirtazapine, and venlafaxine XR were associated with higher rates (36%-43%). In a prospectively defined subpopulation unlikely to have predisposing factors for sexual dysfunction, the prevalence of sexual dysfunction ranged from 7% to 30%, with the odds of having sexual dysfunction 4 to 6 times greater with SSRIs or venlafaxine XR than with bupropion SR. Physicians consistently underestimated the prevalence of antidepressant-associated sexual dysfunction. Ours is the first study to assess sexual dysfunction across the newer antidepressants using consistent methodology and a validated rating scale. Overall, SSRIs and venlafaxine XR were associated with higher rates of sexual dysfunction than bupropion or nefazodone. Because antidepressant-associated sexual dysfunction is considerably underestimated by physicians, greater recognition and education are imperative when prescribing antidepressant treatment.
- 15 April 2002
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 63 (4) , 357-366
Top Cited PapersPrevalence of Sexual Dysfunction Among Newer Antidepressants
Sexual dysfunction commonly occurs during antidepressant treatment. However, the reported rates of sexual dysfunction vary across antidepressants and are typically underreported in product literature. The objectives of this study were (1) to estimate the prevalence of sexual dysfunction among patients taking newer antidepressants (bupropion immediate release [IR], bupropion sustained release [SR], citalopram, fluoxetine, mirtazapine, nefazodone, paroxetine, sertraline, venlafaxine, and venlafaxine extended release [XR]) and (2) to compare physician-perceived with patient-reported prevalence rates of antidepressant-associated sexual dysfunction. This cross-sectional, observational study was conducted in 1101 U.S. primary care clinics. Adult outpatients (4534 women and 1763 men) receiving antidepressant monotherapy were enrolled. The prevalence of sexual dysfunction was measured using the Changes in Sexual Functioning Questionnaire. In the overall population, bupropion IR (22%) and SR (25%) and nefazodone (28%) were associated with the lowest risk for sexual dysfunction, whereas selective serotonin reuptake inhibitor (SSRI) antidepressants, mirtazapine, and venlafaxine XR were associated with higher rates (36%-43%). In a prospectively defined subpopulation unlikely to have predisposing factors for sexual dysfunction, the prevalence of sexual dysfunction ranged from 7% to 30%, with the odds of having sexual dysfunction 4 to 6 times greater with SSRIs or venlafaxine XR than with bupropion SR. Physicians consistently underestimated the prevalence of antidepressant-associated sexual dysfunction. Ours is the first study to assess sexual dysfunction across the newer antidepressants using consistent methodology and a validated rating scale. Overall, SSRIs and venlafaxine XR were associated with higher rates of sexual dysfunction than bupropion or nefazodone. Because antidepressant-associated sexual dysfunction is considerably underestimated by physicians, greater recognition and education are imperative when prescribing antidepressant treatment.
- 1 April 2002
- Published by Elsevier in Clinical Therapeutics
- Vol. 24 (4) , 662-672
Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks
- 1 April 2002
- Published by Elsevier in Clinical Therapeutics
- Vol. 24 (4) , 662-672
Effect on body weight of bupropion sustained-release in patients with major depression treated for 52 weeks
- 15 October 2001
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 62 (10) , 776-781
Do Bupropion SR and Sertraline Differ in Their Effects on Anxiety in Depressed Patients?
From The Journal of Clinical Psychiatry:
- 15 October 2001
- Published by Physicians Postgraduate Press, Inc in The Journal of Clinical Psychiatry
- Vol. 62 (10) , 776-781
Do Bupropion SR and Sertraline Differ in Their Effects on Anxiety in Depressed Patients?
From The Journal of Clinical Psychiatry:
- 1 July 2001
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 25 (1) , 131-138
Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline
Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology, publishing the highest quality original research and advancing our understanding of the brain and behavior.
- 1 July 2001
- Published by Springer Nature in Neuropsychopharmacology
- Vol. 25 (1) , 131-138
Response in Relation to Baseline Anxiety Levels in Major Depressive Disorder Treated with Bupropion Sustained Release or Sertraline
Neuropsychopharmacology, the official publication of the American College of Neuropsychopharmacology, publishing the highest quality original research and advancing our understanding of the brain and behavior.
- 1 May 2001
- Published by Taylor & Francis in Journal of Sex & Marital Therapy
- Vol. 27 (3) , 303-316
Bupropion Sustained Release (SR) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Nondepressed Women
This article describes the results of the first report of bupropion sustained release (SR) in nondepressed females with hypoactive sexual desire disorder (HSDD). Eligible females entered a 4-week, single-blind, placebo baseline phase . Subjects, all of whom did not respond to placebo, continued in a single-blind active treatment phase where they received bupropion SR for up to 8 additional weeks. We assessed HSDD by using investigator ratings of sexual desire and sexual functioning. Of the 51 evaluable subjects who entered the active treatment phase, 29% responded to treatment with bupropion SR. Bupropion SR was generally well tolerated. Pending the results of further study, bupropion SR may offer a treatment option for women with HSDD.
- 1 May 2001
- Published by Taylor & Francis in Journal of Sex & Marital Therapy
- Vol. 27 (3) , 303-316
Bupropion Sustained Release (SR) for the Treatment of Hypoactive Sexual Desire Disorder (HSDD) in Nondepressed Women
This article describes the results of the first report of bupropion sustained release (SR) in nondepressed females with hypoactive sexual desire disorder (HSDD). Eligible females entered a 4-week, single-blind, placebo baseline phase . Subjects, all of whom did not respond to placebo, continued in a single-blind active treatment phase where they received bupropion SR for up to 8 additional weeks. We assessed HSDD by using investigator ratings of sexual desire and sexual functioning. Of the 51 evaluable subjects who entered the active treatment phase, 29% responded to treatment with bupropion SR. Bupropion SR was generally well tolerated. Pending the results of further study, bupropion SR may offer a treatment option for women with HSDD.
- 30 March 2001
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 41 (3) , 248-256
Naratriptan as Short‐Term Prophylaxis of Menstrually Associated Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study
Objective.—To determine the efficacy of naratriptan 1‐mg and 2.5‐mg tablets twice daily compared with placebo as short‐term prophylaxis of menstrually associated migraine.Background.—Approximately 60% of women with migraine report headaches associated with their menstrual cycles. Results from an open‐label study suggest that short‐term administration of sumatriptan is useful in the prophylaxis of menstrually associated migraine.Methods.—A randomized, double‐blind, three‐arm, parallel‐group, placebo‐controlled study was conducted in women aged 18 years or older with a history of migraine with or without aura, as defined by the International Headache Society, of at least 6 months. Two dose strengths of naratriptan (1 mg, 2.5 mg) or identical‐appearing placebo tablets (1:1:1) were administered twice daily for 5 days starting 2 days prior to the expected onset of menses across four perimenstrual periods. End points included the number of menstrually associated migraines, total migraine days, peak headache severity, lost work/activity time, migraine‐related quality of life, and incidence of adverse events.Results.—Overall, the intent‐to‐treat population comprised 206 women (naratriptan 1 mg, n = 70; naratriptan 2.5 mg, n = 70, and placebo, n = 66); 171 women treated four perimenstrual periods. Significantly more perimenstrual periods per subject treated with naratriptan, 1 mg, were headache‐free compared with placebo (50% versus 25%, P = .003). Naratriptan, 1 mg, significantly reduced the number of menstrually associated migraines (2.0 versus 4.0, P < .05) and menstrually associated migraine days (4.2 versus 7.0, P < .01) compared with placebo. More patients treated with naratriptan, 1 mg, were headache‐free across all treated perimenstrual periods compared with placebo (23% versus 8%). No difference in headache severity was observed in breakthrough headaches. The incidence and severity of adverse events was similar across treatment groups. Naratriptan, 2.5 mg, was not statistically superior to placebo for any measure.Conclusions.—Naratriptan, 1 mg, with tolerability similar to placebo, is an effective, short‐term, prophylactic treatment for menstrually associated migraine.
- 30 March 2001
- Published by Wiley in Headache: The Journal of Head and Face Pain
- Vol. 41 (3) , 248-256
Naratriptan as Short‐Term Prophylaxis of Menstrually Associated Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Study
Objective.—To determine the efficacy of naratriptan 1‐mg and 2.5‐mg tablets twice daily compared with placebo as short‐term prophylaxis of menstrually associated migraine.Background.—Approximately 60% of women with migraine report headaches associated with their menstrual cycles. Results from an open‐label study suggest that short‐term administration of sumatriptan is useful in the prophylaxis of menstrually associated migraine.Methods.—A randomized, double‐blind, three‐arm, parallel‐group, placebo‐controlled study was conducted in women aged 18 years or older with a history of migraine with or without aura, as defined by the International Headache Society, of at least 6 months. Two dose strengths of naratriptan (1 mg, 2.5 mg) or identical‐appearing placebo tablets (1:1:1) were administered twice daily for 5 days starting 2 days prior to the expected onset of menses across four perimenstrual periods. End points included the number of menstrually associated migraines, total migraine days, peak headache severity, lost work/activity time, migraine‐related quality of life, and incidence of adverse events.Results.—Overall, the intent‐to‐treat population comprised 206 women (naratriptan 1 mg, n = 70; naratriptan 2.5 mg, n = 70, and placebo, n = 66); 171 women treated four perimenstrual periods. Significantly more perimenstrual periods per subject treated with naratriptan, 1 mg, were headache‐free compared with placebo (50% versus 25%, P = .003). Naratriptan, 1 mg, significantly reduced the number of menstrually associated migraines (2.0 versus 4.0, P < .05) and menstrually associated migraine days (4.2 versus 7.0, P < .01) compared with placebo. More patients treated with naratriptan, 1 mg, were headache‐free across all treated perimenstrual periods compared with placebo (23% versus 8%). No difference in headache severity was observed in breakthrough headaches. The incidence and severity of adverse events was similar across treatment groups. Naratriptan, 2.5 mg, was not statistically superior to placebo for any measure.Conclusions.—Naratriptan, 1 mg, with tolerability similar to placebo, is an effective, short‐term, prophylactic treatment for menstrually associated migraine.
- 1 August 2000
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 75 (8) , 782-789
Effectiveness of Sumatriptan in Reducing Productivity Loss Due to Migraine: Results of a Randomized, Double-Blind, Placebo-Controlled Clinical Trial
- 1 August 2000
- Published by Elsevier in Mayo Clinic Proceedings
- Vol. 75 (8) , 782-789
Effectiveness of Sumatriptan in Reducing Productivity Loss Due to Migraine: Results of a Randomized, Double-Blind, Placebo-Controlled Clinical Trial